125 related articles for article (PubMed ID: 26536349)
21. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors.
Halin S; Wikström P; Rudolfsson SH; Stattin P; Doll JA; Crawford SE; Bergh A
Cancer Res; 2004 Aug; 64(16):5664-71. PubMed ID: 15313905
[TBL] [Abstract][Full Text] [Related]
22. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
[TBL] [Abstract][Full Text] [Related]
23. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
24. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen.
Plymate SR; Tennant M; Birnbaum RS; Thrasher JB; Chatta G; Ware JL
J Clin Endocrinol Metab; 1996 Oct; 81(10):3709-16. PubMed ID: 8855827
[TBL] [Abstract][Full Text] [Related]
25. Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge.
Friedman EJ; Orth CR; Brewton KA; Ponniah S; Alexander RB
J Urol; 1997 Oct; 158(4):1585-8. PubMed ID: 9302178
[TBL] [Abstract][Full Text] [Related]
26. A high-fat diet does not influence the growth of the Dunning R3327-H transplantable prostate adenocarcinoma.
Schwab ED; Normolle D; Pacis RA; Cho SS; Pienta KJ
Anticancer Res; 1998; 18(5A):3603-7. PubMed ID: 9858946
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
28. High-grade tumours promote growth of other less-malignant tumours in the same prostate.
Halin Bergström S; Rudolfsson S; Lundholm M; Josefsson A; Wikström P; Bergh A
J Pathol; 2021 Apr; 253(4):396-403. PubMed ID: 33330991
[TBL] [Abstract][Full Text] [Related]
29. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
[TBL] [Abstract][Full Text] [Related]
30. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
31. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
32. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
Brändström A; Westin P; Bergh A; Cajander S; Damber JE
Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987
[TBL] [Abstract][Full Text] [Related]
33. Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis.
Bussemakers MJ; van de Ven WJ; Debruyne FM; Schalken JA
Cancer Res; 1991 Jan; 51(2):606-11. PubMed ID: 1702360
[TBL] [Abstract][Full Text] [Related]
34. The effect of castanospermine on the metastatic properties of prostate cancer cells.
Yee CS; Schwab ED; Lehr JE; Quigley M; Pienta KJ
Anticancer Res; 1997; 17(5A):3659-63. PubMed ID: 9413219
[TBL] [Abstract][Full Text] [Related]
35. Doxorubicin treatment increases metastasis of prostate tumor (R3327-MatLyLu).
Geldof AA; Rao BR
Anticancer Res; 1988; 8(6):1335-9. PubMed ID: 3218966
[TBL] [Abstract][Full Text] [Related]
36. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
Xia W; Unger P; Miller L; Nelson J; Gelman IH
Cancer Res; 2001 Jul; 61(14):5644-51. PubMed ID: 11454719
[TBL] [Abstract][Full Text] [Related]
37. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression.
Tu H; Jacobs SC; Borkowski A; Kyprianou N
Int J Cancer; 1996 Oct; 69(5):357-63. PubMed ID: 8900367
[TBL] [Abstract][Full Text] [Related]
38. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment.
Halin S; Hammarsten P; Wikström P; Bergh A
Prostate; 2007 Mar; 67(4):370-7. PubMed ID: 17192959
[TBL] [Abstract][Full Text] [Related]
39. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
40. There are multiple forms of glyceraldehyde-3-phosphate dehydrogenase in prostate cancer cells and normal prostate tissue.
Epner DE; Coffey DS
Prostate; 1996 Jun; 28(6):372-8. PubMed ID: 8650074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
